Next-Generation Long-Acting Amylin Drugs for Obesity and Type 2 Diabetes
A review traces the evolution from pramlintide to long-acting amylin analogues, highlighting second-generation non-aggregating peptides advancing through clinical development.
Quick Facts
What This Study Found
Second-generation non-aggregating, long-acting amylin analogues are advancing in clinical development, offering improved dosing convenience over pramlintide.
Key Numbers
How They Did This
Narrative review of amylin biology, receptor structure, peptide design principles, and clinical development of second-generation amylin analogues.
Why This Research Matters
Amylin signaling is a key therapeutic target for next-generation obesity and diabetes drugs, complementary to GLP-1-based approaches.
The Bigger Picture
Amylin analogues could be combined with GLP-1 RAs for enhanced weight loss (as in cagrilintide/semaglutide combinations), potentially surpassing current monotherapy results.
What This Study Doesn't Tell Us
Review of emerging therapies — most second-generation agents are still in clinical trials; long-term safety data pending.
Questions This Raises
- ?Will amylin-GLP-1 RA combinations become the new standard for severe obesity?
- ?What advantage do amylin analogues offer over GLP-1 RAs alone?
Trust & Context
- Key Stat:
- Second-generation amylin drugs Non-aggregating, long-acting analogues advancing through clinical development
- Evidence Grade:
- Narrative review — synthesizes peptide science and clinical development data.
- Study Age:
- Published 2026 in Peptides.
- Original Title:
- Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.
- Published In:
- Peptides, 196, 171480 (2026)
- Authors:
- Bailey, Clifford J(5), Flatt, Peter R(9), Conlon, J Michael(2)
- Database ID:
- RPEP-14819
Evidence Hierarchy
Frequently Asked Questions
What is amylin?
Amylin is a hormone released with insulin after meals that signals fullness to the brain, slows stomach emptying, and suppresses glucagon. New long-acting versions could provide powerful weight loss and blood sugar control.
How do amylin drugs differ from GLP-1 drugs?
Amylin and GLP-1 work through different but complementary pathways. Combining both may produce greater weight loss and metabolic benefits than either alone — this is the rationale behind cagrilintide/semaglutide combinations.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14819APA
Bailey, Clifford J; Flatt, Peter R; Conlon, J Michael. (2026). Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.. Peptides, 196, 171480. https://doi.org/10.1016/j.peptides.2026.171480
MLA
Bailey, Clifford J, et al. "Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.." Peptides, 2026. https://doi.org/10.1016/j.peptides.2026.171480
RethinkPeptides
RethinkPeptides Research Database. "Long-acting amylin-related peptides as therapies for obesity..." RPEP-14819. Retrieved from https://rethinkpeptides.com/research/bailey-2026-longacting-amylinrelated-peptides-as
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.